Abstract: The invention relates to the use of the compound N-[4-beta-(o-anisamide-ethyl)-benzenesulphonyl]-N'-cyclopentylcarbamide and pharmaceutically acceptable salts thereof as well as compositions therewith plus a pharmaceutical carrier to effect glucoreduction activity, that is lowering of blood sugar levels, with reduced possibility of platelet aggregation and therefore of myocardial infarction.